Gene Therapy Market Size, Share & Trends Report

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-cell Lymphoma, Beta-Thalassemia Major/SCD), By Vector Type (Lentivirus, AAV), By Region, And Segment Forecasts, 2021 - 2028

  • Report ID: GVR-2-68038-179-5
  • Number of Pages: 180
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2019
  • Industry: Healthcare

Table of Contents

Chapter 1 Gene Therapy Makret: Executive Summary
                   1.1 Market Summary
Chapter 2 Gene Therapy Makret: Research Methodology
                   2.1 Information Procurement
                   2.2 Information Or Data Analysis
                   2.3 Market Model
                        2.3.1 Historic And Base Year Estimates
                        2.3.2 Forecast Analysis
                        2.3.3 Study Of Approved Therapies By Disease Incidence
                        2.3.4 Study Of Approved Therapies By Vector
                        2.3.5 Region-Wise Approval
Chapter 3 Gene Therapy Makret: Market Variables, Trends, & Scope
                   3.1 Market Trends & Outlook
                   3.2 Market Segmentation
                   3.3 Market Dynamics
                        3.3.1 Market driver analysis
                            3.3.1.1 Robust gene therapy pipeline
                            3.3.1.2 Introduction of technological advancements
                            3.3.1.3 Increasing investment from the companies and partnerships
                            3.3.1.4 Growing prevalence of target diseases and increased demand for innovative medicine
                        3.3.2 Market restraint analysis
                            3.3.2.1 Absence of effective Diagnosis Framework
                            3.3.2.2 High prices of gene therapy
                        3.3.3 Market opportunity analysis
                            3.3.3.1 Rising investment for adoptive T cell transfer approaches of disease treatment
                            3.3.3.2 Facility expansion for cell and gene therapies
                            3.3.3.3 Technological advancements in manufacturing vectors
                        3.3.4 Market challenge analysis
                            3.3.4.1 Production capacity challenges
                            3.3.4.2 Manufacturing challenges pertaining to large-scale production of vectors
                   3.4 Regulatory Framework
                   3.5 Major Deals & Strategic Alliances Analysis
                        3.5.1 Mergers & acquisitions
                        3.5.2 Collaborations & partnerships
                   3.6 Pipeline Analysis
                   3.7 Payment & Pricing Models
                        3.7.1 Payment models for innovative therapies
                   3.8 SWOT analysis, by factor (Political & legal, economic, and technological)
                   3.9 Porter’s Five Forces Analysis
                   3.10 COVID-19 Impact Analysis
                        3.10.1 Key Market Initiatives
                        3.10.2 Conclusion
Chapter 4 Gene Therapy Makret: Indication Business Analysis
                   4.1 Gene therapy market: Indication Movement Analysis
                   4.2 Acute Lymphoblastic Leukemia (ALL)
                        4.2.1 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2017 - 2028 (USD Million)
                   4.3 Inherited Retinal Disease
                        4.3.1 Global gene therapy market for inherited retinal disease, 2017 - 2028 (USD Million)
                   4.4 Large B-cell Lymphoma
                        4.4.1 Global gene therapy market for large B-cell lymphoma, 2017 - 2028 (USD Million)
                   4.5 Adenosine Deaminase (ADA)‐Deficient Severe Combined Immunodeficiency (SCID)
                        4.5.1 Global gene therapy market for ADA-SCID, 2017 - 2028 (USD Million)
                   4.6 Melanoma (Lesions)
                        4.6.1 Global gene therapy market for melanoma (lesions), 2017 - 2028 (USD Million)
                   4.7 Beta-Thalassemia Major/Sickle Cell Disease (SCD)
                        4.7.1 Global gene therapy market for Beta-Thalassemia Major/SCD, 2017 - 2028 (USD Million)
                   4.8 Head & Neck Squamous Cell Carcinoma
                        4.8.1 Global gene therapy market for head & neck squamous cell carcinoma, 2017 - 2028 (USD Million)
                   4.9 Peripheral Arterial Disease
                        4.9.1 Global gene therapy market for peripheral arterial disease, 2017 - 2028 (USD Million)
                   4.10 Spinal Muscular Atrophy (SMA)
                        4.10.1 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2017 - 2028 (USD Million)
                   4.11 Others
                        4.11.1 Global gene therapy market for Others, 2017 - 2028 (USD Million)
Chapter 5 Gene Therapy Makret: Vector Type Business Analysis
                   5.1 Gene Therapy Market: Vector Type Movement Analysis
                   5.2 Gene Therapy Market: Technology Movement Analysis
                   5.3 Lentiviral Vectors
                        5.3.1 Global lentivirus-based gene therapy market, 2017 - 2028 (USD Million)
                   5.4 Adeno-Associated Viral (AAV) Vectors
                        5.4.1 Global AAV-based gene therapy market, 2017 - 2028 (USD Million)
                   5.5 RetroVirus & gamma RetroVirus Vectors
                        5.5.1 Global RetroVirus & gamma RetroVirus vectors-based gene therapy market, 2017 - 2028 (USD Million)
                   5.6 Modified Herpes Simplex Virus
                        5.6.1 Global modified herpes simplex virus vectors-based gene therapy market, 2017 - 2028 (USD Million)
                   5.7 Adenovirus Vectors
                        5.7.1 Global adenovirus vectors -based gene therapy market, 2017 - 2028 (USD Million)
                   5.8 Non-viral Plasmid
                        5.8.1 Global Non-viral plasmid-based gene therapy market, 2017 - 2028 (USD Million)
Chapter 6 Gene Therapy Makret: Regional Business Analysis
                   6.1 Gene Therapy Market Share, By Region
                   6.2 Gene Therapy Market: Regional Movement Analysis
                   6.3 North America
                        6.3.1 North America Gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
                        6.3.2 The U.S.
                            6.3.2.1 The U.S. gene therapy market, by indication, 2017 - 2028 (USD Million)
                            6.3.2.2 The U.S. gene therapy market, by vector type, 2017 - 2028 (USD Million)
                        6.3.3 Canada
                            6.3.3.1 Canada gene therapy market, by indication, 2017 - 2028 (USD Million)
                            6.3.3.2 Canada gene therapy market, by vector type, 2017 - 2028 (USD Million)
                   6.4 Europe
                        6.4.1 Europe gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
                   6.5 Asia Pacific
                        6.5.1 Asia Pacific gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
                        6.5.2 Japan
                            6.5.2.1 Japan gene therapy market, by indication, 2017 - 2028 (USD Million)
                            6.5.2.2 Japan gene therapy market, by vector type, 2017 - 2028 (USD Million)
                        6.5.3 China
                            6.5.2.1 China gene therapy market, by indication, 2017 - 2028 (USD Million)
                            6.5.2.2 China gene therapy market, by vector type, 2017 - 2028 (USD Million)
                        6.5.4 Russia
                            6.5.4.1 Russia gene therapy market, by indication, 2017 - 2028 (USD Million)
                            6.5.4.2 Russia gene therapy market, by vector type, 2017 - 2028 (USD Million)
                        6.5.5 Australia
                            6.5.5.1 Australia gene therapy market, by indication, 2017 - 2028 (USD Million)
                            6.5.5.2 Australia gene therapy market, by vector type, 2017 - 2028 (USD Million)
                   6.6 RoW
                        6.6.1 RoW gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
Chapter 7 GENE THERAPY MAKRET: COMPANY Profiles
                   7.1 Company Profiles
                        7.1.1 REGENXBIO, Inc.
                            7.1.1.1 Company overview
                            7.1.1.2 Financial performance
                            7.1.1.3 Product benchmarking
                            7.1.1.4 Strategic Initiatives
                        7.1.2 Oxford BioMedica plc
                            7.1.2.1 Company overview
                            7.1.2.2 Financial performance
                            7.1.2.3 Product benchmarking
                            7.1.2.4 Strategic Initiatives
                        7.1.3 Voyager Therapeutics
                            7.1.3.1 Company overview
                            7.1.3.2 Financial performance
                            7.1.3.3 Product benchmarking
                            7.1.3.4 Strategic Initiatives
                        7.1.4 Human Stem Cells Institute
                            7.1.4.1 Company overview
                            7.1.4.2 Financial performance
                            7.1.4.3 Product benchmarking
                            7.1.4.4 Strategic Initiatives
                        7.1.5 Dimension Therapeutics, Inc.
                            7.1.5.1 Company overview
                                7.1.5.1.1 Financial performance
                            7.1.5.2 Product benchmarking
                            7.1.5.3 Strategic Initiatives
                        7.1.6 Bristol-Myers Squibb Company
                            7.1.6.1 Company overview
                                7.1.6.1.1 Celgene Corporation
                            7.1.6.2 Financial performance (Bristol-Myers Squibb)
                                7.1.6.2.1 Financial performance (Celgene Corporation)
                            7.1.6.3 Product benchmarking (Bristol-Myers Squibb)
                                7.1.6.3.1 Product benchmarking (Celgene)
                            7.1.6.4 Strategic Initiatives
                        7.1.7 Sanofi
                            7.1.7.1 Company overview
                            7.1.7.2 Financial performance
                            7.1.7.3 Product benchmarking
                            7.1.7.4 Strategic Initiatives
                        7.1.8 Applied Genetic Technologies Corporation
                            7.1.8.1 Company overview
                            7.1.8.2 Financial performance
                            7.1.8.3 Product benchmarking
                            7.1.8.4 Strategic Initiatives
                        7.1.9 F. Hoffmann-La Roche Ltd.
                            7.1.9.1 Company overview
                                7.1.9.1.1 Spark Therapeutics, Inc.
                            7.1.9.2 Financial performance
                                7.1.9.2.1 Financial performance
                            7.1.9.3 Product benchmarking
                            7.1.9.4 Strategic Initiatives
                        7.1.10 bluebird Bio, Inc.
                            7.1.10.1 Company overview
                            7.1.10.2 Financial performance
                            7.1.10.3 Product benchmarking
                            7.1.10.4 Strategic Initiatives
                        7.1.11 Novartis AG
                            7.1.11.1 Company overview
                                7.1.11.1.1 AveXis, Inc.
                            7.1.11.2 Financial performance
                                7.1.11.2.1 Financial performance (AveXis)
                            7.1.11.3 Product benchmarking
                            7.1.11.4 Strategic Initiatives
                                7.1.11.4.1 Strategic Initiatives
                        7.1.12 Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
                            7.1.12.1 Company overview
                            7.1.12.2 Financial performance
                            7.1.12.3 Product benchmarking
                            7.1.12.4 Strategic Initiatives
                        7.1.13 UniQure N.V.
                            7.1.13.1 Company overview
                            7.1.13.2 Financial performance
                            7.1.13.3 Product benchmarking
                            7.1.13.4 Strategic Initiatives
                        7.1.14 Shire Plc
                            7.1.14.1 Company overview
                            7.1.14.2 Financial performance
                            7.1.14.3 Product benchmarking
                            7.1.14.4 Strategic Initiatives
                        7.1.15 Cellectis S.A.
                            7.1.15.1 Company overview
                            7.1.15.2 Financial performance
                            7.1.15.3 Product benchmarking
                            7.1.15.4 Strategic Initiatives
                        7.1.16 Sangamo Therapeutics, Inc.
                            7.1.16.1 Company overview
                            7.1.16.2 Financial performance
                            7.1.16.3 Product benchmarking
                            7.1.16.4 Strategic Initiatives
                        7.1.17 Orchard Therapeutics
                            7.1.17.1 Company overview
                            7.1.17.2 Financial performance
                            7.1.17.3 Product benchmarking
                            7.1.17.4 Strategic Initiatives
                        7.1.18 Gilead Lifesciences, Inc.
                            7.1.18.1 Company overview
                            7.1.18.2 Financial Performance
                            7.1.18.3 Product benchmarking
                            7.1.18.4 Strategic Initiatives
                        7.1.19 BENITEC BIOPHARMA
                            7.1.19.1 Company overview
                            7.1.19.2 Financial Performance
                            7.1.19.3 Product benchmarking
                            7.1.19.4 Strategic Initiatives
                        7.1.20 Sibiono GeneTech Co., Ltd
                            7.1.20.1 Company overview
                            7.1.20.2 Product benchmarking
                        7.1.21 Shanghai Sunway Biotech Co., Ltd.
                            7.1.21.1 Company overview
                            7.1.21.2 Product benchmarking
                        7.1.22 Gensight Biologics S.A.
                            7.1.22.1 Company overview
                            7.1.22.2 Financial performance
                            7.1.22.3 Product benchmarking
                            7.1.22.4 Strategic initiatives
                        7.1.23 Transgene
                            7.1.23.1 Company overview
                            7.1.23.2 Financial performance
                            7.1.23.3 Product benchmarking
                            7.1.23.4 Strategic initiatives
                        7.1.24 Calimmune, Inc.
                            7.1.24.1 Company overview
                            7.1.24.2 Product benchmarking
                            7.1.24.3 Strategic initiatives
                        7.1.25 Epeius Biotechnologies Corp.
                            7.1.25.1 Company overview
                            7.1.25.2 Financial performance
                            7.1.25.3 Product benchmarking
                        7.1.26 Astellas Pharma Inc.
                            7.1.26.1 Company overview
                            7.1.26.2 Audentes Therapeutics, Inc.
                                7.1.26.2.1 Company overview
                            7.1.26.3 Financial performance
                                7.1.26.3.1 Financial performance
                            7.1.26.4 Product benchmarking
                            7.1.26.5 Strategic initiatives
                        7.1.27 American Gene Technologies
                            7.1.27.1 Company overview
                            7.1.27.2 Product benchmarking
                            7.1.27.3 Strategic initiatives
                        7.1.28 BioMarin Pharmaceuticals, Inc.
                            7.1.28.1 Company overview
                            7.1.28.2 Financial performance
                            7.1.28.3 Product benchmarking
                            7.1.28.4 Strategic initiatives


List of Tables

TABLE 1 Ongoing projects for CAR T-cell therapies
TABLE 2 Non-viral DNA vectors (non-replicating) in gene therapy trials
TABLE 3 Some of the examples of molecules under development based on lentiviral vectors
TABLE 4 Molecules in development based on AAV vectors
TABLE 5 North America gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 6 North America gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 7 The U.S. gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 8 The U.S. gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 9 Canada gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 10 Canada gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 11 Europe gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 12 Europe gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 13 Asia Pacific gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 14 Asia Pacific gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 15 China gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 16 China gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 17 Japan gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 18 Japan gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 19 Russia gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 20 Russia gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 21 Australia gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 22 Australia gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 23 RoW gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 24 RoW gene therapy market, by vector type, 2017 - 2028 (USD Million)


List of Figures

FIG. 1 Market summary (USD Million)
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value chain based sizing & forecasting
FIG. 7 QFD modelling for market share assessment
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Global gene therapy pipeline as of 2017, by phase of trial
FIG. 12 Global cancer incidence, as of 2019/2020
FIG. 13 Market restraint relevance analysis (Current & future impact)
FIG. 14 Gene therapy prices by eligible patients per year
FIG. 15 Annual Investment in the CAR-T Space, 2013-2026
FIG. 16 Global financings in cell therapy, 2017-2019
FIG. 17 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017
FIG. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 19 Porter’s Five Forces Analysis
FIG. 20 Gene therapy market: Indication type outlook key takeaways
FIG. 21 Gene therapy market: Indication type movement analysis
FIG. 22 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2017 - 2028 (USD Million)
FIG. 23 Global gene therapy market for inherited retinal disease, 2017 - 2028 (USD Million)
FIG. 24 Global gene therapy market for large B-cell lymphoma, 2017 - 2028 (USD Million)
FIG. 25 Global gene therapy market for ADA-SCID, 2017 - 2028 (USD Million)
FIG. 26 Global gene therapy market for melanoma (lesions), 2017 - 2028 (USD Million)
FIG. 27 Global gene therapy market for Beta-Thalassemia Major/SCD, 2017 - 2028 (USD Million)
FIG. 28 Global gene therapy market for head & neck squamous cell carcinoma, 2017 - 2028 (USD Million)
FIG. 29 Global gene therapy market for peripheral arterial disease, 2017 - 2028 (USD Million)
FIG. 30 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2017 - 2028 (USD Million)
FIG. 31 Global gene therapy market for other indications, 2017 - 2028 (USD Million)
FIG. 32 Gene therapy market vector type outlook: Key takeaways
FIG. 33 Gene therapy market: Vector type movement analysis
FIG. 34 Global lentivirus-based gene therapy market, 2017 - 2028 (USD Million)
FIG. 35 Global AAV-based gene therapy market, 2017 - 2028 (USD Million)
FIG. 36 Global retrovirus vectors-based gene therapy market, 2017 - 2028 (USD Million)
FIG. 37 Global modified herpes simplex virus vectors -based gene therapy market, 2017 - 2028 (USD Million)
FIG. 38 Global adenovirus vectors -based gene therapy market, 2017 - 2028 (USD Million)
FIG. 39 Global plasmids-based gene therapy market, 2017 - 2028 (USD Million)
FIG. 40 Regional market place: Key takeaway
FIG. 41 Gene therapy regional outlook, 2020 & 2028
FIG. 42 North America gene therapy market, 2017 - 2028 (USD Million)
FIG. 43 The U.S. gene therapy market, 2017 - 2028 (USD Million)
FIG. 44 Canada gene therapy market, 2017 - 2028 (USD Million)
FIG. 45 Europe gene therapy market, 2017 - 2028 (USD Million)
FIG. 46 Asia Pacific gene therapy market, 2017 - 2028 (USD Million)
FIG. 47 China gene therapy market, 2017 - 2028 (USD Million)
FIG. 48 Japan gene therapy market, 2017 - 2028 (USD Million)
FIG. 49 Russia gene therapy market, 2017 - 2028 (USD Million)
FIG. 50 Australia gene therapy market, 2017 - 2028 (USD Million)
FIG. 51 RoW gene therapy market, 2017 - 2028 (USD Million)
FIG. 52 Strategy framework

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.